CN113559260A - anti-Human Papilloma Virus (HPV) e6e7 private gel component and production process thereof - Google Patents
anti-Human Papilloma Virus (HPV) e6e7 private gel component and production process thereof Download PDFInfo
- Publication number
- CN113559260A CN113559260A CN202110944024.2A CN202110944024A CN113559260A CN 113559260 A CN113559260 A CN 113559260A CN 202110944024 A CN202110944024 A CN 202110944024A CN 113559260 A CN113559260 A CN 113559260A
- Authority
- CN
- China
- Prior art keywords
- hpv
- gel
- human papilloma
- papilloma virus
- private
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the technical field of medical gel, and discloses a component of anti-Human Papilloma Virus (HPV) E6E7 private gel and a production process thereof, wherein the component comprises gel HPV-L1-E/7-lgY, and the gel comprises the following main components of a sophora flavescens extract: 4-6%, wherein other components of the gel comprise egg yolk globulin powder, a fructus cnidii extract, a cortex phellodendri extract, safflower, horsetail, rhizoma cyperi, menthol, hydroxyethyl cellulose and sodium hyaluronate, the gel has the bacteriostatic categories of staphylococcus aureus, escherichia coli and candida albicans, the gel has an inactivation effect on HPV18 type pseudovirus, and the detection result shows that the virus titer of a virus control group is 5.01x107ffu/ml, e6e7 of the sample tested@The virus titer of the private bacteriostatic gel group is less than 1.67x102ffu/ml. According to the anti-Human Papilloma Virus (HPV) e6e7 private gel component and the production process, the private bacteriostatic gel can play a bacteriostatic role on staphylococcus aureus, escherichia coli and candida albicans, and can effectively inhibit Human Papilloma Virus (HPV).
Description
Technical Field
The invention relates to the technical field of medical gel, in particular to an anti-Human Papilloma Virus (HPV) e6e7 private gel component and a production process thereof.
Background
Drugs are substances used for the prevention, treatment and diagnosis of diseases. In theory, all chemical substances that can affect the physiological functions of organs and the metabolic activities of cells belong to the category of drugs.
The bacteriostatic gel is a medical drug prepared aiming at different bacterial colonies, is colloidal and can inhibit the bacterial colonies.
Human Papilloma Virus (HPV) infection can cause tumor lesion of cervical epithelial part, and the traditional physical therapy is difficult to obtain better curative effect.
At present, some medicines can not well inhibit and prevent recurrence of Human Papilloma Virus (HPV), so an anti-Human Papilloma Virus (HPV) e6e7 private gel component and a production process are urgently needed.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides an anti-Human Papilloma Virus (HPV) e6e7 private gel component and a production process thereof, which have the advantages of good inhibition and relapse prevention for Human Papilloma Virus (HPV) and the like, and solve the problem that some medicaments cannot well inhibit and prevent the Human Papilloma Virus (HPV).
(II) technical scheme
In order to achieve the purpose, the invention provides the following technical scheme: an anti-Human Papilloma Virus (HPV) E6E7 private gel component and a production process thereof, comprises gel HPV-L1-E/7-lgY, wherein the gel mainly comprises sophora flavescens extract: 4-6% of matrine.
Preferably, the other ingredients of the gel comprise egg yolk globulin powder, fructus Cnidii extract (osthole), cortex Phellodendri extract (berberine), Carthami flos, herba Equiseti hiemalis, rhizoma Cyperi, menthol, hydroxyethyl cellulose and sodium hyaluronate.
The product is forbidden in menstrual period, can avoid wound and sensitive skin, is forbidden for children, and is forbidden for young, virgin, pregnant women, parturient, and lactation period, if discomfort exists, the product should be stopped using, and washed with clear water, and is not used for preventing sexual transmitted disease in sexual life.
Preferably, the gel inhibition classes are staphylococcus aureus, escherichia coli, and candida albicans.
Preferably, the gel has an inactivation effect on HPV18 pseudovirus, and the detection result shows that the virus titer of a virus control group is 5.01x107ffu/ml, e6e7 of the sample tested@The virus titer of the private bacteriostatic gel group is less than 1.67x102ffu/ml。
Preferably, the eggyin antibody (IgY) is a 7s immunoglobulin, Human Papilloma Virus (HPV), and the eggyin antibody IgY has a specific functional structure, can be combined with HPV capsid protein of human papilloma virus to reduce the infectivity of Human Papilloma Virus (HPV) and assist the positive negative transformation of cervical HPV infection.
Preferably, the sample to be tested e6e7@The private bacteriostatic gel reduces HPV18 type pseudovirus titer by more than 5.48log under the condition of 37 ℃ water bath for 4 hours, and the fire extinguishing rate is more than 99.9997%.
Preferably, the gel is applicable to blocking genital Human Papilloma Virus (HPV) infection, reducing Human Papilloma Virus (HPV) load, preventing cervical lesion from occurring, blocking Human Papilloma Virus (HPV) infection, treating fart lesion caused by Human Papilloma Virus (HPV) infection, reducing recurrence rate of condyloma acuminatum after physical therapy, and is a non-sterile product for disposable use.
Compared with the prior art, the invention provides an anti-Human Papilloma Virus (HPV) e6e7 private gel component and a production process thereof, and the invention has the following beneficial effects:
1. the anti-Human Papilloma Virus (HPV) e6e7 private gel component and the production process can treat staphylococcus aureus through the private bacteriostatic gel. The escherichia coli and the candida albicans play a role in inhibiting bacteria, can effectively inhibit Human Papilloma Virus (HPV), and can well inhibit, clean and remove odor of private parts of women.
Drawings
FIG. 1 is a graph comparing negative conversion rates of two groups according to the present invention;
FIG. 2 is a graph comparing the cure rates of two groups of the present invention;
FIG. 3 is a graph showing a comparison of the non-adverse reaction rates of the present invention;
FIG. 4 shows the invention e6e7@The effect of the private bacteriostatic gel on extinguishing the HPV18pp is shown.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example one
An example of an anti-Human Papilloma Virus (HPV) e6e7 intimate gel component:
referring to FIGS. 1-4, a personal gel composition of Human Papilloma Virus (HPV) E6E7 and process for preparation thereof, including HPV-L1-E/7-lgY, the gel comprises radix Sophorae Flavescentis extract as main ingredient: 4-6% of matrine.
Specifically, the other components of the gel comprise egg yolk globulin powder, fructus Cnidii extract (osthole), cortex Phellodendri extract (berberine), Carthami flos, herba Equiseti hiemalis, rhizoma Cyperi, menthol, hydroxyethyl cellulose and sodium hyaluronate.
Specifically, the gel bacteriostasis categories are staphylococcus aureus, escherichia coli and candida albicans.
By adopting the technical scheme, the product is forbidden in menstrual period, avoids wound and sensitive skin, is placed at the position which cannot be touched by children, is forbidden in immature, virgin, pregnant women, lying-in women and lactation period, and is not required to be used and washed by clean water if discomfort exists, and the sexual life can be prevented.
Example two
Example of inactivation of privacy gel fraction of anti-Human Papilloma Virus (HPV) e6e7
Specifically, the gel has an inactivation effect on HPV18 pseudovirus, and the detection result shows that the virus titer of a virus control group is 5.01x107ffu/ml, e6e7 of the sample tested@The virus titer of the private bacteriostatic gel group is less than 1.67x102ffu/ml。
Specifically, the sample to be tested e6e7@The private bacteriostatic gel reduces HPV18 type pseudovirus titer by more than 5.48log under the condition of 37 ℃ water bath for 4 hours, and the fire extinguishing rate is more than 99.9997%.
Specifically, the gel has the application range of blocking genital Human Papilloma Virus (HPV) infection, reducing Human Papilloma Virus (HPV) load, preventing cervical lesion, blocking Human Papilloma Virus (HPV) infection, being used for fart lesion caused by Human Papilloma Virus (HPV) infection, reducing recurrence rate of condyloma acuminatum after physical therapy, and being a non-sterile product for disposable use.
By the technical scheme, the value is e6e7 in fig. 4@The effect of the private bacteriostatic gel on the fire extinguishing effect of HPV18pp, "+" indicates the presence of fluorescent spots, "-" indicates the absence of fluorescent spots, and the numerical values indicate the number of fluorescent spots counted per well, which result may be caused by the virucidal effect of the sample on HPV18 pseudovirus or the pseudovirus of the sample on HPV18Caused by the neutralization of the virus.
EXAMPLE III
Example of clinical efficacy of a manufacturing process of an anti-Human Papilloma Virus (HPV) e6e7 private gel
Basic data of patients: 300 randomly selected female high-risk HPY infection concurrent CIN (I, I) patients were used as study subjects, the diagnosis time was 2016 (2) months to 2018 (9) months, and the study subjects were randomly divided into an observation group (152 cases) and a control group (148 cases). Through statistical analysis, the two groups of patients have no significant difference in age and basic physical condition (P > 0.05);
the treatment method comprises the following steps: three groups of patients are subjected to physical treatment within 2-5 days after recent menstruation, the physical treatment and the operation part are subjected to local anesthesia treatment, the pathological change part is marked by medical marking liquid, pathological change related tissues are cut in a non-colored area, and the cutting degree is controlled to be 15-20 mm so as to avoid damaging the normal tissues of the patients. After the operation is finished, the conventional anti-infection treatment is carried out. After physical therapy and operation are finished, a gynecological cleaning device which is additionally provided with a functional gel containing a Relinta anti-IgY polyclonal antibody composite copper phytate is added to a patient in an observation group, the gynecological cleaning device is inserted into a vagina for treatment, the treatment period is 3 months, one piece is used every day in the 1 st month, and one piece is used every other day in the 2 nd and 3 rd months (except for menstrual period), so that a complete treatment time course is formed, (wherein the physical therapy comprises laser, microwave, freezing, electrocautery, LEEP knife, photodynamic therapy and the like);
and (4) investigation indexes are as follows: the follow-up visit of the patients is carried out for 25 weeks averagely, wherein the follow-up contents comprise hr-HPV-DHA negative conversion rate, CIN cure rate and the condition of adverse reaction caused by operation;
and (3) statistical treatment: performing data analysis by using SPSS20.0, and checking counting data by using a chi-square method;
the analysis structure of FIG. 1 is that the hr-HPV-DHA negative conversion rate of the observation group patients receiving the functional gel combination physical therapy is 96.65%, which is obviously higher than that of the control group patients receiving the physical therapy, and the difference is very obvious (P < 0.05);
the analysis result of figure 2 shows that the CIN cure rate of the patients in the observation group receiving the functional gel and physical therapy is 97.89%, which is obviously higher than that of the patients in the control group receiving the physical therapy, and the difference is very obvious, namely P is less than 0.05). The detailed data are shown in Table 2;
FIG. 3 shows that the total incidence of the side effects of the patients in the observation group is 3.65%, the total incidence of the side effects of the patients in the control group is 18.58%, and the incidence of the side effects of the patients in the observation group is significantly lower than that of the patients in the control group (P <0.05). the detailed data are shown in Table 3;
follow-up visit is carried out on three groups of patients for 25 weeks, the HPV negative turning rate and abnormal leucorrhea rate of the three groups of patients are recorded during the follow-up visit, and the HPV infection treatment effect and the treatment effective rate of chronic cervicitis and gynecological inflammatory diseases are analyzed according to the HPV negative turning rate and abnormal leucorrhea rate;
HPV negative conversion rate: the HPV negative conversion rate of the patients in the treatment group is 92.85%, while the control group and the blank group are 55.21% and 19.96% respectively, and P is less than 0.05;
abnormal leucorrhea: the abnormal reduction rate of the leucorrhea of the patients in the treatment group is 96.87 percent, while the abnormal reduction rate of the leucorrhea of the control group and the blank group is 51.74 percent and 10.22 percent respectively, and P is less than 0.05.
Example four
Example of ProductionProcess of Imidaoglobulin antibody (IgY) against Human Papilloma Virus (HPV) e6e7 private gel
Specifically, the eggylin antibody (IgY) is a 7s immunoglobulin, Human Papilloma Virus (HPV), and the eggylin antibody IgY has a specific functional structure, can be combined with HPV capsid protein of the human papilloma virus to reduce the infection power of the Human Papilloma Virus (HPV), and assists the positive negative conversion of cervical HPV infection.
Through the technical scheme, the egg yolk is selectively transferred to the hen serum and is the only immunoglobulin in the egg yolk, and the components can still keep certain activity at the pasteurization temperature and in the acidic environment of the vagina;
clinical application data 1:
500 cases of patients with HPV infection complicated with chronic cervicitis and gynecological diseases were selected. Experimental groups: 170 cases; control group: 168 cases, using c. -2b + Baofukang suppositories; blank group: 162 cases, placebo;
observation indexes are as follows: HPV negative-turning rate and gynecological inflammation effectiveness (abnormal reduction of leucorrhea);
and (4) conclusion: (1) the negative conversion rate of the anti-HPV IgY gel for treating HPV infection is up to 92.85%, which is 38% higher than that of a control group, and the difference of the two groups has statistical significance (p is less than 0.05);
(2) the effective rate of the traditional Chinese medicine for treating chronic cervicitis and gynecological inflammation is 96.87%, the effective rate is 45% higher than that of a control group, and the difference of the two groups has statistical significance (p is less than 0.05);
clinical application data 2:
among 120 cases of HPV infection patients, the high-risk type is mainly 16, 18, 31, 45, 52 and 58 types, and the low-risk type is mainly 6, 11, 42 and 81 types;
the treatment lasts for 3 months, and the follow-up is carried out after 8 weeks. The total effective rate of the interferon treatment group is 63.3 percent, and the total effective rate of the treatment group is 96.6 percent;
the yolk antibody has better effect on eliminating specific HPV infection than recombinant human interferon a-2b treatment, has no obvious adverse reaction, and can be used for preventing and treating HPV infection;
positive cervical HPV infection:
following the medical advice, the continuous use is recommended for 3 months as a treatment course (except menstrual period), the second treatment course can be used every other day, the reexamination is recommended after 1-2 treatment courses, and the use scheme is adjusted according to the improvement condition of the curative effect;
patients with local symptoms such as syndrogenitis cervicitis, cervical erosion, nanocapsule, inflammatory cervical hypertrophy and the like need to be actively treated (povidone iodine powder or cervicitis treatment support is adopted or operation treatment is performed if necessary);
cervical HPV infection prevention use recommendations:
the medicine can be continuously used for two days every weekend or continuously used for one week every month, and can be continuously used for two weeks except for menstrual period for patients with gynecological inflammation related symptoms;
the HPV virus DNA in the early stage of the virus is not integrated into host DNA cells, HPV can generate more coat protein in host cells, and host cells (cervical columnar epithelium) infected with HPV are not malignant and are easy to recognize, so that the HPV virus DNA is the optimal stage for eliminating HPV infection;
once the "transient infection" is converted into the "persistent infection, after the virus is integrated into the DNA of a host, the HPV does not produce coat protein, is difficult to be recognized by an immune system and is difficult to remove;
if the host cell is induced to develop cervical precancerous lesion or cervical cancer, the treatment cost and the damage to women are obviously increased.
When in use, before use, the female cleans the vulva part, then bends the knee and lies on the back, takes down the sleeve at the front end of the injector, slightly pushes the push tube into the deep vagina, injects the product into the vagina completely, and then takes out the product slowly, so as to avoid the movement in three minutes as far as possible, thereby avoiding the outflow.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (7)
1. An anti-Human Papilloma Virus (HPV) E6E7 intimate gel component comprising gel HPV-L1-E/7-lgY characterized in that: the gel comprises matrine 4-6% extracted from radix Sophorae Flavescentis and myosin antibody IgY.
2. The anti-Human Papillomavirus (HPV) e6e7 intimate gel fraction of claim 1, wherein: the other components of the gel comprise egg yolk globulin powder, fructus Cnidii extract (osthole), cortex Phellodendri extract (berberine), Carthami flos, herba Equiseti hiemalis, rhizoma Cyperi, menthol, hydroxyethyl cellulose and sodium hyaluronate.
3. The anti-Human Papillomavirus (HPV) e6e7 intimate gel fraction of claim 1, wherein: the gel inhibition classes are staphylococcus aureus, escherichia coli and candida albicans.
4. The anti-Human Papillomavirus (HPV) e6e7 intimate gel fraction of claim 1, wherein: the gel has an inactivation effect on HPV18 pseudovirus, and the detection result shows that the virus isControl group virus titer was 5.01 × 107ffu/ml, e6e7 of the sample tested@The virus titer of the private bacteriostatic gel group is less than 1.67x102ffu/ml。
5. The anti-Human Papillomavirus (HPV) e6e7 intimate gel fraction of claim 1, wherein: the egg yolk globulin antibody IgY is a 7s immunoglobulin, Human Papilloma Virus (HPV), has a specific functional structure, can be combined with HPV capsid protein to reduce the infection power of the HPV, and assists the positive transformation of cervical HPV infection into negative.
6. The production process of the private gel of anti-Human Papilloma Virus (HPV) e6e7 is characterized by comprising the following steps: sample to be tested e6e7@The private bacteriostatic gel reduces HPV18 type pseudovirus titer by more than 5.48log under the condition of 37 ℃ water bath for 4 hours, and the fire extinguishing rate is more than 99.9997%.
7. The production process of the private gel of anti-Human Papilloma Virus (HPV) e6e7 is characterized by comprising the following steps: the gel has the application range of blocking genital Human Papilloma Virus (HPV) infection, reducing the Human Papilloma Virus (HPV) load, preventing cervical lesion, blocking Human Papilloma Virus (HPV) infection, being used for fart lesion caused by Human Papilloma Virus (HPV) infection, reducing recurrence rate of condyloma acuminatum after physical treatment, and being a non-sterilized product for disposable use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110944024.2A CN113559260A (en) | 2021-08-17 | 2021-08-17 | anti-Human Papilloma Virus (HPV) e6e7 private gel component and production process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110944024.2A CN113559260A (en) | 2021-08-17 | 2021-08-17 | anti-Human Papilloma Virus (HPV) e6e7 private gel component and production process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113559260A true CN113559260A (en) | 2021-10-29 |
Family
ID=78171927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110944024.2A Pending CN113559260A (en) | 2021-08-17 | 2021-08-17 | anti-Human Papilloma Virus (HPV) e6e7 private gel component and production process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113559260A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711785A (en) * | 2005-05-09 | 2010-05-26 | 蔡有龄 | Traditional Chinese medicine for treating human papillomavirus infection |
| CN112618713A (en) * | 2021-01-06 | 2021-04-09 | 周陶 | anti-HPV and anti-gynecological inflammation composite ovovitellin composition and gel |
| CN112999345A (en) * | 2021-01-21 | 2021-06-22 | 郑州世纪亿佰商贸有限公司 | Formula of gel for preventing and treating cervical HPV infection |
-
2021
- 2021-08-17 CN CN202110944024.2A patent/CN113559260A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711785A (en) * | 2005-05-09 | 2010-05-26 | 蔡有龄 | Traditional Chinese medicine for treating human papillomavirus infection |
| CN112618713A (en) * | 2021-01-06 | 2021-04-09 | 周陶 | anti-HPV and anti-gynecological inflammation composite ovovitellin composition and gel |
| CN112999345A (en) * | 2021-01-21 | 2021-06-22 | 郑州世纪亿佰商贸有限公司 | Formula of gel for preventing and treating cervical HPV infection |
Non-Patent Citations (1)
| Title |
|---|
| 李利霞: ""瑞琳他抗IgY多克隆抗体复合植酸铜功能性凝胶联合物理治疗高危HPV感染合并CIN的临床疗效分析", 《医药前沿》, pages 123 - 124 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Logan et al. | Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis | |
| CN103721131B (en) | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease | |
| CN107456509B (en) | A kind of external application biological agent and preparation method for vagina prevention, health care and treatment gynaecology genital inflammation | |
| JP6923147B2 (en) | Chinese herbal medicine composition for treating diseases caused by human papillomavirus, its preparation method and use | |
| CN112999345A (en) | Formula of gel for preventing and treating cervical HPV infection | |
| CN113559260A (en) | anti-Human Papilloma Virus (HPV) e6e7 private gel component and production process thereof | |
| CN105012702B (en) | Application of the externally-applied skin-generating oil in the drug of preparation prevention or treatment diabetic distal dyshaemia and ulcer of foot | |
| CN103405653B (en) | External preparation for treating gouty arthritis | |
| CN106177007B (en) | Traditional Chinese medicine suppository for treating cervical diseases caused by high-risk HPV persistent infection and preparation method thereof | |
| CN1911260A (en) | Application of phenolic acids active components from dandelion for inhibiting gynecologic pelvic inflammatory disease | |
| CN100435808C (en) | Chinese medicine for treating dermatosis and tumor | |
| CN103285332A (en) | Pharmaceutical composition for promoting post-operation wound healing | |
| Sharpe et al. | Exophthalmos due to sterile neutrophilic dermatosis in a dog | |
| CN1899412A (en) | Suppository for treating gynecopathy and its preparing method | |
| CN108514640A (en) | Medical composition and its use containing pokeweed antiviral protein and immunologic active material | |
| Tungsukruthai et al. | Adverse drug reaction and preliminary efficacy of Dioscorea bulbifera Linn. gel on wound healing in Thai patients | |
| CN110882301A (en) | Ointment for treating hemorrhoids and using method thereof | |
| Kumari et al. | Clinical Evaluation Of Efficacy Of Kusthadi Churna With Udumbaradi Tail In The Management Of Karnini Yonivyapada WSR To Cervical Erosion | |
| Chandran et al. | Management of Charmakeela (Anal Warts) with Agnikarma by electrocautery-along with Adjuvant Ayurvedic Remedies: A Case Report | |
| Ordiyants et al. | Recurrence of HPV infection after combination therapy of uterine cervical diseases | |
| CN104306819B (en) | It is a kind of to treat Chinese medicine composition of NUG and preparation method thereof | |
| CN118178539A (en) | Use of nasopharyngeal disinfectant for preventing and treating oral epidermoid carcinoma | |
| Parvin et al. | A review study on Agni karma and Kshara karma in the management of Garbha Saya Grivamukhagata Vrana (cervical erosion) | |
| CN104771619B (en) | A kind of preparation method for the treatment of the medicine of cervical erosion | |
| CN118576644A (en) | Sore-healing granulation-promoting antibacterial traditional Chinese medicine composition, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |